Evidence map›Paper›PMID 41230834›Full record

ArticleJournal of cellular and molecular medicine2025

Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets.

Shan Tang, Feng Ren, Wei Hou, Zihao Fan, Yinkang Mo, Xianru Zhu, Yaling Cao, Ling Xu, Sujun Zheng

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. [Development and validation of a machine learning-based prediction model for fatty liver in Wilson disease].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  2. Article
  3. [Research progress of inherited liver disease in 2025].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shan TangFirst Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Feng RenBeijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China.
Wei HouFirst Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zihao FanBeijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yinkang MoBeijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xianru ZhuBeijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yaling CaoBeijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ling XuBeijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China.
Sujun ZhengFirst Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-8228-2819

Funding

Beijing Hospitals Authority's Ascent Plan DFL20241701Beijing Municipal Health Commission (Academic Leader-02-14)Beijing Science and Technology New Star Program 20230484455National Natural Science Foundation of China Youth Project Category C 82502232
6 · The paper itself

Abstract

Wilson disease (WD) is an inherited disorder caused by ATP7B mutations, resulting in toxic copper accumulation primarily in the liver and brain. While copper-induced hepatotoxicity is a hallmark of WD, the mechanisms linking copper overload to liver injury remain unclear. This study aimed to investigate the role of cuproptosis, a copper-dependent form of regulated cell death, in WD pathogenesis and identify key cuproptosis-related genes (CRGs). We utilised ATP7B-/- mice and HepG2 cells to model WD. Liver injury was assessed histologically and biochemically. Transcriptomic analysis identified differentially expressed CRGs, followed by machine learning (LASSO, SVM-RFE) to identify key genes. Functional enrichment and protein validation were performed. Candidate biomarkers were evaluated in WD patient serum and confirmed in the mouse model. ATP7B-/- mice showed marked hepatocellular injury with elevated AST, ALT and LDH. Cuproptosis markers (FDX1, DLST, DLAT, LIAS) were upregulated in both liver tissue and HepG2 cells. Copper exposure decreased cell viability and increased LDH release, exacerbated by Elesclomol and alleviated by Tetrathiomolybdate. Transcriptomics revealed Lox, App, Afp, Alb, Gpc1, Gls were central hub genes. Importantly, SiRNA knockdown of Gpc1, Gls, Lox and App alleviated cuproptosis, supporting their key roles in cuproptosis. Cuproptosis plays a critical role in copper-induced liver injury in WD. Key mediators identified include Gpc1, Gls, Lox and App, which were validated as potential therapeutic targets. These findings provide new insights into the molecular mechanisms underlying WD and may inform the development of targeted treatment strategies.

Indexed as

CopperCopper-Transporting ATPasesHepatolenticular DegenerationAnimalsBiomarkersDisease Models, AnimalGene Expression ProfilingHep G2 CellsHumansLiverMaleMiceMice, KnockoutATP7B protein, humanBiomarkersCopperCopper-Transporting ATPasescuproptosisdiagnostic biomarkersdifferentially expressed geneshub genestherapeutic targetsWilson disease

Identifiers

PMID41230834
PMCPMC12613164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.